70.76
price up icon0.01%   0.01
pre-market  Pre-market:  71.10   0.34   +0.48%
loading
Ani Pharmaceuticals Inc stock is traded at $70.76, with a volume of 385.84K. It is up +0.01% in the last 24 hours and up +4.66% over the past month. ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$70.75
Open:
$70.83
24h Volume:
385.84K
Relative Volume:
1.26
Market Cap:
$1.49B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
86.29
EPS:
0.82
Net Cash Flow:
$100.45M
1W Performance:
+2.63%
1M Performance:
+4.66%
6M Performance:
+19.91%
1Y Performance:
+8.03%
1-Day Range:
Value
$69.99
$72.57
1-Week Range:
Value
$68.12
$72.57
52-Week Range:
Value
$52.50
$72.57

Ani Pharmaceuticals Inc Stock (ANIP) Company Profile

Name
Name
Ani Pharmaceuticals Inc
Name
Phone
(218) 634-3500
Name
Address
210 MAIN STREET WEST, BAUDETTE, MN
Name
Employee
897
Name
Twitter
Name
Next Earnings Date
2024-12-08
Name
Latest SEC Filings
Name
ANIP's Discussions on Twitter

Compare ANIP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
ANIP
Ani Pharmaceuticals Inc
70.76 1.49B 486.82M 18.78M 100.45M 0.82
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
155.43 66.90B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.28 48.25B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.28 47.13B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.58 16.06B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
300.76 13.15B 2.76B 1.11B 898.10M 22.77

Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-14-25 Initiated Jefferies Buy
Mar-12-25 Initiated JP Morgan Overweight
Dec-11-24 Initiated Leerink Partners Outperform
Oct-11-24 Initiated Piper Sandler Overweight
Mar-15-24 Initiated CapitalOne Overweight
Aug-22-23 Reiterated H.C. Wainwright Buy
Mar-01-23 Initiated Guggenheim Buy
Sep-07-22 Initiated H.C. Wainwright Buy
Nov-02-21 Initiated Truist Buy
May-07-20 Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-12-19 Initiated Guggenheim Buy
May-10-19 Downgrade Raymond James Strong Buy → Outperform
Oct-16-17 Reiterated Canaccord Genuity Buy
Jul-31-17 Initiated Canaccord Genuity Buy
Feb-22-17 Downgrade ROTH Capital Buy → Neutral
Jun-23-16 Initiated Raymond James Strong Buy
May-24-16 Downgrade Standpoint Research Buy → Hold
Nov-13-15 Initiated Standpoint Research Buy
Sep-28-15 Upgrade ROTH Capital Neutral → Buy
Aug-05-15 Reiterated Oppenheimer Outperform
Aug-04-15 Reiterated ROTH Capital Neutral
Jul-31-15 Reiterated Oppenheimer Outperform
Jul-15-15 Reiterated ROTH Capital Neutral
Jun-23-15 Reiterated Oppenheimer Outperform
May-18-15 Reiterated ROTH Capital Neutral
May-06-15 Reiterated Oppenheimer Outperform
Apr-10-15 Downgrade ROTH Capital Buy → Neutral
Feb-26-15 Reiterated ROTH Capital Buy
Feb-18-15 Reiterated Oppenheimer Outperform
View All

Ani Pharmaceuticals Inc Stock (ANIP) Latest News

pulisher
Apr 29, 2025

The 4.0% return this week takes ANI Pharmaceuticals' (NASDAQ:ANIP) shareholders three-year gains to 135% - simplywall.st

Apr 29, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 24, 2025

Zacks.com featured highlights include Heritage Insurance, Marex, Kingstone, ANI Pharmaceuticals and HCI - TradingView

Apr 24, 2025
pulisher
Apr 23, 2025

Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Zacks.com featured highlights include ANI Pharmaceuticals, Heritage Insurance, Avista and Exelon - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue - TradingView

Apr 23, 2025
pulisher
Apr 21, 2025

Truist raises ANI Pharmaceuticals target to $65, maintains hold - Investing.com India

Apr 21, 2025
pulisher
Apr 21, 2025

Truist raises ANI Pharmaceuticals target to $65, maintains hold By Investing.com - Investing.com Canada

Apr 21, 2025
pulisher
Apr 21, 2025

Truist Lifts Price Target on ANI Pharmaceuticals to $65 From $62, Keeps Hold Rating - marketscreener.com

Apr 21, 2025
pulisher
Apr 17, 2025

ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance

Apr 17, 2025
pulisher
Apr 15, 2025

ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance

Apr 15, 2025
pulisher
Apr 15, 2025

ANI Pharmaceuticals (ANIP): Buy, Sell, Or Hold Post Q4 Earnings? - Barchart.com

Apr 15, 2025
pulisher
Apr 14, 2025

Ani Pharmaceuticals Sr. VP sells $27,583 in stock By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 13, 2025

StockNews.com Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Sell - MarketBeat

Apr 13, 2025
pulisher
Apr 11, 2025

Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

ANI Pharmaceuticals (ANIP) Set for Potential Earnings Beat - GuruFocus

Apr 11, 2025
pulisher
Apr 09, 2025

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - GlobeNewswire

Apr 09, 2025
pulisher
Apr 09, 2025

ANI Pharmaceuticals Reveals Q1 2025 Earnings Date: Key Executive Insights Coming May 9 - Stock Titan

Apr 09, 2025
pulisher
Apr 08, 2025

Zacks.com featured highlights ANI Pharmaceuticals, Expand Energy, Avista Corp and Contango ORE - Yahoo Finance

Apr 08, 2025
pulisher
Apr 07, 2025

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Apr 07, 2025
pulisher
Apr 07, 2025

Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO - TradingView

Apr 07, 2025
pulisher
Apr 03, 2025

ANI Pharmaceuticals at RBC Conference: Strategic Growth in Rare Diseases By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 03, 2025

Is The Options Market Predicting A Spike In ANI Pharmaceuticals (ANIP) Stock? - Barchart.com

Apr 03, 2025
pulisher
Apr 03, 2025

Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance

Apr 03, 2025
pulisher
Apr 03, 2025

ANI Pharmaceuticals To Present At RBC Capital Markets Conference; Webcast At 7:45 AM ET - Nasdaq

Apr 03, 2025
pulisher
Apr 02, 2025

Zacks.com featured highlights include HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree - Yahoo Finance

Apr 02, 2025
pulisher
Mar 31, 2025

ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewswire

Mar 31, 2025
pulisher
Mar 28, 2025

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st

Mar 28, 2025
pulisher
Mar 25, 2025

5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio - TradingView

Mar 25, 2025
pulisher
Mar 24, 2025

Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance

Mar 24, 2025
pulisher
Mar 24, 2025

Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross? - Zacks Investment Research

Mar 24, 2025
pulisher
Mar 21, 2025

Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Mar 21, 2025
pulisher
Mar 20, 2025

Alimera Sciences announces change to SmPC allowing all United Kingdom (Great Britain and Northern Ireland) qualified ophthalmic healthcare professionals experienced in intravitreal injections to administer ILUVIEN - PharmiWeb.com

Mar 20, 2025
pulisher
Mar 19, 2025

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

ANI Pharmaceuticals Launches Kionex Suspension For Electrolyte Imbalance Management: Key Trend Transforming... - WhaTech

Mar 19, 2025
pulisher
Mar 19, 2025

ANI Pharmaceuticals launches generic Nitazoxanide Tablets By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Ani Pharmaceuticals Launches Nitazoxanide Tablets for Treating Diarrhea -March 19, 2025 at 09:33 am EDT - MarketScreener

Mar 19, 2025
pulisher
Mar 19, 2025

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

ANI Pharmaceuticals launches generic Nitazoxanide Tablets - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

ANI Pharmaceuticals Announces The Launch Of Nitazoxanide Tablets -March 19, 2025 at 06:51 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan

Mar 19, 2025
pulisher
Mar 19, 2025

ANI Pharmaceuticals settles royalty obligation for $17.25 million By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

ANI Pharmaceuticals Eliminates Royalty Obligation On ILUVIEN And YUTIQ - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

ANI Pharmaceuticals settles royalty obligation for $17.25 million - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

ANI Pharma buys Iluvien and Yutiq royalties (ANIP:NASDAQ) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

ANI Pharma buys royalties linked to Iluvien and Yutiq - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq -March 18, 2025 at 08:20 am EDT - Marketscreener.com

Mar 18, 2025

Ani Pharmaceuticals Inc Stock (ANIP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$28.77
price up icon 3.08%
$103.96
price up icon 1.23%
$8.34
price up icon 1.09%
$107.24
price up icon 0.73%
drug_manufacturers_specialty_generic RDY
$13.94
price up icon 0.00%
$300.76
price up icon 1.25%
Cap:     |  Volume (24h):